Pretium Resources Inc (NYSE:PVG) is high on the list of small-cap gainers after regulators gave the Canadian gold producer the green light to boost production at its Brucejack Mine in northern British Columbia. Under amended permits worked out with the British Columbia Ministry of Energy, Mines and Petroleum Resources and the BC Ministry of Environment and Climate Change Strategy, the production rate at BruceJack will increase to 3,800 tonnes per day. The new deals allow for Pretium’s production at the mine to increase to an annual rate of 1.387 million tonnes from 0.99 million tonnes.
Pretium shares jumped 8.2% to $8.03.
Shares of Jack in the Box (NASDAQ:JACK) are also climbing on news that the burger chain is reaching out to buyers about a possible sale. While its management has held talks with would-be buyers, no commitment has been made and other options are still under consideration. If the company’s plans for a sale fail, it will look to change its capital structure in ways that could include a securitization or bond issuance. Jack in the Box, which operates more than 2,200 restaurants, has been hit hard by decreased consumer demand for fast food as well as the challenge of paying higher wages to its workers.
Jack in the Box picked up 4% to $83.65.
READ: CryptoCann™ Report: Bitmain faces an IPO obstacle; Ontario to limit number of private dispensaries
Ameris Bancorp shares (NASDAQ:ABCB) are taking a tumble after entering into a merger with a rival bank Fidelity Southern Corporation of Georgia, which is worth $750.7 million. Already approved by the two banks’ boards, the deal allows Fidelity shareholders to receive 0.8 Ameris shares per Fidelity share. The price of the merger, which values Fidelity Southern shares at $27.22, represents a 27% premium to Fidelity’s closing price of $21.42 on Friday. Ameris is headquartered in Jacksonville, Florida.
Ameris shed 3.8% to $32.72.
Atara Biotherapeutics Inc (NASDAQ:ATRA) is also slipping on the back of the release of new clinical results by the T-cell immunotherapy company. In a recent study, twelve patients suffering from Epstein-Barr and leiomyosarcoma, a rare soft tissue sarcoma that resists radiation and chemotherapy, were treated with Atara’s tab-cel (tabelecleucel) Of the 10 patients assessed, two saw a partial response while eight patients achieved stable disease. Tab-cel was generally well-tolerated and safe, Atara said. Based in South San Francisco, California, Atara develops new T cell immune therapy treatments to fight cancer as well as autoimmune and viral diseases.
Atara shares shed 7.3% to $38.70.